Basic Medicine, Oncology

Antibody Drug Development

Development of Cancer-specific Monoclonal Antibodies without Side Effects

Medical Sciences Course

  • Master / Doctor Degree

Faculty

KATO, YukinariKATO, Yukinari
KATO, Yukinari

Professor, M.D. Ph.D.

  • TEL

    +81-22-717-8207

  • Mail

    yukinarikato*med.tohoku.ac.jp (Please convert "*" into "@".)

*Concurrent Position

Research Theme

  • Development of innovative next generation cancer-specific monoclonal antibodies and clinical application
  • Protein expression and antibody production using antibody-engineering technologies
  • Development of therapeutic devices using tumor-specific antibodies
Research Keywords:

podoplanin, CLEC-2, PA tag, IDH1/2, CasMab

Technical Keywords:

cancer-specific monoclonal antibody, glycobiology, development of therapeutic devices, monoclonal antibody, antibody-engineering

Laboratory Introduction

Although many antigens are expressed highly in tumors, those antigens have been removed from the candidates of antibody-drug targets because they were also expressed in normal tissues. When one protein in cancer cells and normal cells possesses the same amino acid sequence, the post-translational difference such as glycans should be utilized to produce the cancer-specific mAb (CasMab). The CasMab method is the platform to develop mAbs, which could attack only cancer cells. Importantly, this method is useful for not only producing CasMabs against novel targets but also replace the existing mAbs into the side effect-free ones. Podoplanin, a cancer metastasis-inducing protein, is expressed in many cancers, while it is also expressed in normal cells such as lymphatic endothelial cells and lung type I alveolar cells. We have already produced CasMabs against human podoplanin. We will refine our technologies and develop CasMabs against several molecular targets.

Figure 1. Podoplanin is expressed in many cancers

Figure 1. Podoplanin is expressed in many cancers

Figure 2. Development of cancer-specific monoclonal antibodies

Figure 2. Development of cancer-specific monoclonal antibodies

Recent Publications

  • Kato Y, Kaneko MK. A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin. Sci Rep. 4:5924, 2014
  • Nagae M, et al. A novel platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and non-glycosylated rhodocytin. Structure. 22(12): 1711?1721, 2014
  • Kaneko M, et al. IDH2 mutation is frequently observed in giant cell tumor of bone. Cancer Sci. 105(6):744-748, 2014
  • Fujii Y, et al. PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr Purif. 95:240-247, 2014
  • Kato Y. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol. 32(1): 3-11, 2015